Shanghai Pharmaceuticals Book Value Per Share vs. EBITDA

601607 Stock   21.93  0.51  2.38%   
Based on Shanghai Pharmaceuticals' profitability indicators, Shanghai Pharmaceuticals Holding may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Shanghai Pharmaceuticals' ability to earn profits and add value for shareholders.
For Shanghai Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Shanghai Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Shanghai Pharmaceuticals Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Shanghai Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Shanghai Pharmaceuticals Holding over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Shanghai Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shanghai Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shanghai Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Shanghai Pharmaceuticals EBITDA vs. Book Value Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Shanghai Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Shanghai Pharmaceuticals Holding is number one stock in book value per share category among its peers. It also is number one stock in ebitda category among its peers totaling about  502,813,870  of EBITDA per Book Value Per Share. At present, Shanghai Pharmaceuticals' EBITDA is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Shanghai EBITDA vs. Book Value Per Share

Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Shanghai Pharmaceuticals

Book Value per Share

 = 

Common Equity

Average Shares

 = 
19.13 X
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Shanghai Pharmaceuticals

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
9.62 B
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Shanghai EBITDA Comparison

Shanghai Pharmaceuticals is currently under evaluation in ebitda category among its peers.

Shanghai Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Shanghai Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Shanghai Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Shanghai Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Shanghai Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income9.6 B10 B
Income Before Tax7.1 B7.4 B
Net Income Applicable To Common Shares5.9 B6.2 B
Net Income3.8 B2.2 B
Income Tax Expense2.1 B2.2 B
Net Income From Continuing Ops5.2 B5.4 B
Total Other Income Expense Net-1.5 B-1.4 B
Net Interest Income-1.3 B-1.3 B
Interest Income461.8 M315.1 M
Change To Netincome1.2 B1.4 B

Shanghai Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Shanghai Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Shanghai Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Shanghai Pharmaceuticals' important profitability drivers and their relationship over time.

Use Shanghai Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Shanghai Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Shanghai Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Shanghai Pharmaceuticals Pair Trading

Shanghai Pharmaceuticals Holding Pair Trading Analysis

The ability to find closely correlated positions to Shanghai Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Shanghai Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Shanghai Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Shanghai Pharmaceuticals Holding to buy it.
The correlation of Shanghai Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Shanghai Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Shanghai Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Shanghai Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Shanghai Pharmaceuticals position

In addition to having Shanghai Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Copper Thematic Idea Now

Copper
Copper Theme
Companies involved in production of copper. The Copper theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Copper Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Shanghai Stock

To fully project Shanghai Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Shanghai Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Shanghai Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Shanghai Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Shanghai Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Shanghai Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Shanghai Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.